Safety and Efficacy Study of ISIS 301012 (Mipomersen) Administration in High Risk Statin Intolerant Subjects
Status:
Completed
Trial end date:
2011-01-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine safety and efficacy of mipomersen (ISIS 301012) in
the reduction of total cholesterol, low density lipoprotein cholesterol (LDL-C), and
apolipoprotein B (apoB) in high risk subjects intolerant to statins.